Bio-Techne (TECH) Long-Term Investments (2010 - 2026)
Bio-Techne's quarterly Long-Term Investments came in at $231.0 million in Q1 2026, up 1440.19% year-on-year from $15.0 million in Q1 2025, and down 1.71% quarter-over-quarter from $235.0 million in Q4 2025.
Bio-Techne has reported Long-Term Investments for 14 years, with the latest figure at $231.0 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 1440.19% year-over-year to $231.0 million; the trailing twelve-month figure through Mar 2026 stood at $231.0 million (up 1440.19% YoY), and the FY2025 full-year result was $236.0 million, down 2.62% from the prior year.
- Long-Term Investments for Q1 2026 stood at $231.0 million, down from $235.0 million in the prior quarter.
- The five-year high for Long-Term Investments was $257.0 million in Q1 2023, with the low at $15.0 million in Q4 2024.
- Average Long-Term Investments over 5 years is $174.2 million, with a median of $235.5 million recorded in 2025.
- Year-over-year, Long-Term Investments tumbled 93.99% in 2024 and jumped 1466.91% in 2025.
- Tracing TECH's Long-Term Investments over 5 years: stood at $25.0 million in 2022, then surged by 898.92% to $249.7 million in 2023, then plunged by 93.99% to $15.0 million in 2024, then jumped by 1466.91% to $235.0 million in 2025, then slipped by 1.71% to $231.0 million in 2026.
- The last three Long-Term Investments figures came in at $231.0 million (Q1 2026), $235.0 million (Q4 2025), and $234.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | 231.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 231.03 Mn |
| Dec 31, 2025 | 235.04 Mn |
| Sep 30, 2025 | 234.93 Mn |
| Jun 30, 2025 | 235.98 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 241.31 Mn |
| Jun 30, 2024 | 242.34 Mn |
| Mar 31, 2024 | 247.98 Mn |
| Dec 31, 2023 | 249.73 Mn |
| Sep 30, 2023 | 251.64 Mn |
| Jun 30, 2023 | 255.86 Mn |
| Mar 31, 2023 | 257.00 Mn |
| Dec 31, 2022 | 25.00 Mn |
| Sep 30, 2022 | 25.00 Mn |
| Jun 30, 2022 | 25.00 Mn |
| Jun 30, 2020 | 6.60 Mn |
| Jun 30, 2018 | 2.61 Mn |
| Mar 31, 2018 | 24.18 Mn |
| Dec 31, 2017 | 40.39 Mn |
| Sep 30, 2017 | 40.39 Mn |
| Jun 30, 2017 | 40.39 Mn |
| Mar 31, 2017 | 40.39 Mn |
| Dec 31, 2016 | 40.00 Mn |
| Jun 30, 2016 | 385,000.00 |
| Sep 30, 2014 | 3.58 Mn |
| Jun 30, 2014 | 3.58 Mn |
| Mar 31, 2014 | 151.36 Mn |
| Dec 31, 2013 | 162.59 Mn |
| Sep 30, 2013 | 138.48 Mn |
| Jun 30, 2013 | 132.38 Mn |
| Mar 31, 2013 | 135.77 Mn |
| Dec 31, 2012 | 128.57 Mn |
| Sep 30, 2012 | 131.71 Mn |
| Jun 30, 2012 | 1.06 Mn |
| Mar 31, 2012 | 1.52 Mn |
| Dec 31, 2011 | 148.11 Mn |
| Sep 30, 2011 | 19.44 Mn |
| Jun 30, 2011 | 131.99 Mn |
| Mar 31, 2011 | 19.82 Mn |
| Dec 31, 2010 | 20.01 Mn |
| Sep 30, 2010 | 161.52 Mn |
| Jun 30, 2010 | 171.17 Mn |